Cell-Based Quadrivalent Influenza Vaccines Outperform Egg-Based Counterparts in Preventing Test-Confirmed Influenza

Researchers compared the effectiveness of cell- and egg-based quadrivalent influenza vaccines (QIVc and QIVe, respectively) in preventing test-confirmed influenza over three US influenza seasons (2017-2020). The study, conducted by the Center for Outcomes Research, found that QIVc demonstrated superior effectiveness in preventing test-confirmed influenza in children and adults, with relative vaccine effectiveness (rVE) of 14.8% in 2017-2018, 12.5% in 2018-2019, and 10.0% in 2019-2020.

Key Takeaways:

• The study analyzed 31,824, 33,388, and 34,398 patients in the 2017-2018, 2018-2019, and 2019-2020 seasons, respectively.
• Approximately 10% of patients received QIVc and 90% received QIVe.
• QIVc demonstrated superior effectiveness in preventing test-confirmed influenza in 2017-2018, 2018-2019, and 2019-2020 seasons.
• The study found that cell-based quadrivalent influenza vaccines were superior to egg-based ones in preventing test-confirmed influenza among children and adults.
• The research concluded that these findings corroborate previously published relative effectiveness studies of cell- vs egg-based quadrivalent influenza vaccines.

Statistics:

• The study included 31,824 patients in the 2017-2018 season, with 10% receiving QIVc and 90% receiving QIVe.
• The study included 33,388 patients in the 2018-2019 season, with 10% receiving QIVc and 90% receiving QIVe.
• The study included 34,398 patients in the 2019-2020 season, with 10% receiving QIVc and 90% receiving QIVe.
• QIVc demonstrated superior effectiveness in preventing test-confirmed influenza, with rVE of 14.8% in 2017-2018, 12.5% in 2018-2019, and 10.0% in 2019-2020.

Sources:

• Open Forum Infectious Diseases
• Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA
• Center for Outcomes Research
• Center for Outcomes Research & Epidemiol, CSL Seqirus, Melbourne, Australia